Execution Matters: Why The Right CDMO Partner Defines Success

Choosing a CDMO is about far more than technical capabilities and available capacity. In small molecule development, where synthetic pathways are increasingly complex and regulatory expectations continue to rise, execution has become a critical differentiator. Success often hinges on factors that are harder to evaluate during a standard qualification process, including process chemistry expertise, communication practices, organizational alignment, and the ability to retain and apply knowledge throughout development and manufacturing.

This perspective explores how execution gaps contribute to delays, rework, regulatory challenges, and rising program costs, even when the underlying science is strong. It also highlights practical ways sponsors can assess a potential partner’s ability to deliver consistent results, from evaluating project teams and exception management practices to examining documentation quality and technology transfer capabilities. With supply chain resilience and regulatory readiness now central considerations, organizations are increasingly looking beyond price and infrastructure when selecting external partners.

Learn what distinguishes a technically capable vendor from a true development and manufacturing partner, and why that distinction can have a lasting impact on program success